Curacle (CEO Jae-Hyun Yoo) announced on November 12th that its patent for CU106, a combination therapy under development as an immune-oncology drug, has been approved for registration in China.

According to the company, CU106 is part of a project to expand the indications of CU06. CU06, designed to block endothelial dysfunction, is being developed for retinal diseases such as diabetic macular edema and wet age-related macular degeneration. The same compound is being developed under the names CU104 and CU106 for ulcerative colitis and combination therapy with immune-oncology drugs, respectively.

Curacle explains that CU106 enhances the efficacy of immune-oncology drugs by improving the tumor microenvironment (TME) and activating T-cell function.

A company representative stated, "In addition to securing the Chinese patent for CU106, we plan to establish exclusive patent rights in major countries that account for a significant portion of the global pharmaceutical market. This will support our efforts to seamlessly prepare for a 'one-package deal' involving CU06, CU104, and CU106."